Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Walnut allergen-specific B-cell receptors (BCRs) are specialized membrane-bound immunoglobulins expressed on the surface of B lymphocytes that selectively bind to proteins derived from walnuts, such as Jug r 1, Jug r 2, and Jug r 3 (Heeringa et al., 2021). These receptors are central to the development and maintenance of walnut allergy, as their activation leads to the production of allergen-specific IgE antibodies (Ellebedy et al., 2016). When a sensitized individual is exposed to walnut, these IgE antibodies facilitate the cross-linking of FcεRI receptors on mast cells and basophils, resulting in the release of inflammatory mediators and potentially fatal anaphylaxis (Costa et al., 2021). Therapeutic strategies targeting these BCRs aim to achieve long-term desensitization or a cure by selectively depleting the B cell clones responsible for the allergic response. Emerging modalities include B-cell Antigen Receptor-targeting T cells (BAR-T cells), which are engineered to recognize and kill B cells expressing specific BCRs, thereby halting the production of pathogenic IgE (Basner-Tschakarjan et al., 2019). This precision medicine approach represents a significant shift from traditional symptom management toward targeting the underlying cellular drivers of food allergy.
Selective depletion of allergen-specific B cells and induction of immune tolerance through antigen-specific interaction.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Walnut allergen-specific B-cell receptor (Walnut-specific BCR).